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The pathology shared by the heterogeneous group of glaucoma disorders is progressive optic nerve damage that is characterized by 'cupping' of the optic disk. This progressive glaucomatous optic atrophy gradually leads to visual field loss. The precise mechanisms leading to optic nerve axon damage have not been fully elucidated. Intuitively, direct treatment of the optic nerve is an obvious therapeutic strategy; however, there are no completed clinical trials that have tested the proof-of-concept that 'neuroprotection' is a viable treatment for glaucoma. 2 At present, ophthalmologists treat the only known modifiable risk factor for glaucoma, clinically significant elevated intraocular pressure (IOP).
Given our current understanding of the human genome and glaucoma therapeutics, the question is, are there genetic determinants for the pharmacodynamic variation in drug response to glaucoma medications? In order to begin to answer this question we need to assess the following two issues: (1) What is the evidence that lowering IOP is important for 'protecting' the susceptible optic nerve in patients with glaucoma? (2) What are the variables in assessing the IOP response to glaucoma medications?
The first issue has been addressed in five randomized clinical trials, and the results provide strong evidence that reducing IOP slows the progression of glaucomatous optic neuropathy. In the Advanced Glaucoma Intervention Study (AGIS), there was a clear IOP 'dose-response' relationship with visual field progression which showed a striking lack of visual field progression in patients who had a mean IOP of 12.3 mmHg. 3 In the other four trials, the treatment interventions, which included medications, laser or filtration surgeries, were based on either setting a minimum target pressure [Ocular Hypertension Treatment Study (OHTS) 4 and Early Manifest Glaucoma Trial Group (EMGT) 5 ], calculated target pressure (Collaborative Initial Glaucoma Treatment Study 6 ) or percent IOP lowering (OHTS, EMGT and Collaborative Normal Tension Glaucoma Study 7 ). Based on these trials, there has been a shift in reporting the effectiveness of glaucoma drugs. Prior to 1996 most glaucoma pharmacology trials reported efficacy as a 'mean IOP' and the standard deviations or standard errors of the mean. Now, more studies report on 'percent IOP reduction' as an index of response to glaucoma medications.
The second issue may be addressed by investigating the basic pharmacology of glaucoma therapeutics. There are five major classes of glaucoma medications: muscarinic cholinergic agonists, carbonic anhydrase inhibitors, b-adrenergic receptor (AR) antagonists, a 2 -AR agonists, and prostaglandin F receptor agonists. Though nonselective AR agonists had been used, their use is now extremely limited because they are not as effective compared to the newer drugs. The mechanism of action of these drugs is directed either to decrease the production of the clear intraocular fluid (aqueous humor) by the ciliary body or to enhance the outflow of aqueous humor through the trabecular meshwork and/or uveoscleral pathway ( Figure 1 ). Elevated IOP is usually caused by outflow obstruction, 9 and not from increased aqueous humor secretion. There are some susceptible optic nerves that sustain damage at normal IOPs. 7 Despite our understanding of the pharmacology of these medications, we cannot explain the variable IOP response to glaucoma drugs between patients. The IOP response to a drug has been reported in numerous formats: mean IOP pretreatment, mean IOP post-treatment, change in IOP, target IOP, percent change in IOP, effect on diurnal IOP, 'clinical success,' percent subjects achieving a specified target IOP, and 'nonresponders' (Figure 2 ). Important considerations to interpret the drug effect properly include: IOP at drug peak and trough effect, contralateral effect in monocular placebo-controlled trials, regression to the mean, placebo effect, and definitions of 'clinical success' and 'nonresponders.' 10 In pharmacology trials, the safety and efficacy data of a drug are based on a biased population of 'homogeneous subjects' who met specific inclusion and exclusion criteria. Although these criteria are important to minimize confounding effects of various ocular conditions, systemic diseases and medications, such study designs explain why unusual and infrequent drug reactions are identified in a 'post-marketing' setting when the drug is widely used in patients who deviate from the 'average clinical trial subject.' 11 The variations in the pharmacodynamic response of drug-mediated IOP lowering are due to a combination of factors: compliance, biological mechanisms, ocular and systemic conditions, environmental factors, and genetics ( Figure 2 ). If compliance is affirmed, then variability in drug response is attributed to physiological and biochemical factors of the targeted cells, which may be modified by extrinsic and intrinsic factors. The extrinsic factors include diet, chemicals, tobacco, alcohol, and other drugs (environmental factors). The intrinsic factors include age, gender, weight, disease state, and genetics, which fall into the intersecting factors of 'genetics' and 'eye and systemic diseases and biology.' Despite the complexity of these multifactorial attributes, the variability in drug response can be studied by the fundamental methods of pharmacology relating to pharmacokinetics and pharmacodynamics.
The earliest reported variation in ocular drug response was the differential mydriatic effect of cocaine, ephedrine, and anti-muscarinic agents in lightly pigmented compared to darkly pigmented eyes. 12 This observation was initially attributed to ethnoracial differences, enzymatic differences, and an 'atypical muscarinic receptor' of the iris sphincter of darkly pigmented eyes. This variable effect was determined to be due to differences in drug distribution using standard radioligand binding methods. Increased nonspecific binding to melanin meant that the higher melanin content of darkly pigmented eyes decreased the bioavailability of these drugs to the target receptors. 13 The effectiveness of timolol 0.25% was reported to be less in brown eyes compared with blue eyes at 1 h after dosing, and this finding was attributed to excess pigmentation. 14 An example of the interaction between eye disease and IOP response is angle-closure mechanisms of glaucoma, where medical therapy is not a definitive treatment strategy because the elevated IOP relates to mechanical obstruction of outflow. Another consideration of drug response variations is race. Despite the controversy surrounding ethnoracial profiling in medical research, it is clear that certain alleles vary among different populations derived from a common ancestry and may prove to be important in treating the individual patient. 15 In the glaucoma literature, there is evidence that timolol is 'notably less' effective in blacks than in nonblacks. 16 In a 'responder analysis' comparing timolol, travoprost and latanoprost, timolol was less effective in black patients compared to nonblack patients. 8 Also of interest was the OHTS finding that African Americans who were treated with calcium-channel blockers did not respond as well as Caucasians in the beta blocker treated eye. 17 An explanation for this statistical observation is not clear, but the use of a systemic medication would be considered an 'environmental variable' that can impact the effectiveness of a drug. Neither of these aforementioned studies reported on an analysis based on iris color, regardless of race, to test whether iris pigmentation and possible nonspecific binding of the drug may be a factor in the response analysis. 13 In addition, none of these aforementioned studies had a genetic component to determine whether there was an association between specific alleles of the drug targets and the therapeutic response. Understanding the reasons for these variable clinical responses based on race and disease state has begun to be studied on the basis of single nucleotide polymorphisms (SNPs) and haplotypes in the drug target genes. 18 Most drug response variations are of the Gaussian type, which tend to be viewed as environmentally determined, 19 but usually have some definable hereditary elements. 20 Another drug response distribution is bimodal (two dichotomous groups of 'nonresponders' and 'responders') which contrasts the discordant phenotypes at the tails of the Gaussian distribution of a continuous phenotype. The tails of the Gaussian distribution curves are of clinical interest with those at the lower limits identified as 'nonresponders' and those at the upper limits classified as 'super responders.' Such a distribution in response is clearly evident in aqueous humor flow in normal subjects 21 and in the IOP response of the contralateral eye to topical beta blockers in patients enrolled in OHTS. 17 Given these response distributions for aqueous humor flow and IOP response to topical beta blockers, it is reasonable to hypothesize that SNPs in candidate genes contribute to these ocular response variations.
A candidate gene approach is a logical and reasonable approach to test the hypothesis that genetic determinants contribute to the variation in drug-mediated IOP response. The candidate genes relevant to IOP response include: drug targets, associated downstream signaling molecules, transporters, ion channels, enzymes, and drug metabolizing enzymes (see Table 1 ). Characterizing the expression of these genes within the ocular tissue targets is a fundamental step before embarking on the laborious effort of identifying SNPs in these genes. The ciliary body has been intensively studied due to its importance in regulating aqueous humor dynamics, and all three classes of ARs, the a 1 -, a 2 -, and b-ARs, have been identified using pharmacological and physiological approaches. The a 1 -ARs do not appear to have a substantial role in aqueous humor dynamics, so these receptors are not considered priority genes for IOP response. Among the three b-AR subtypes, it is believed that the b 2 -AR predominates over b 1 -AR. 22 Using molecular approaches, we found that only the b 2 -AR transcript was expressed in the ciliary epithelium, which is thought to be discrete tissue of the ciliary body that is responsible for aqueous humor secretion, and that both b 1 -and b 2 -AR transcripts, but not the b 3 -AR, were expressed in the entire ciliary body. 23 Among the three a 2 -ARs subtypes, the a 2A -AR subtype is predominant in ciliary body based on radioligand binding. 24 However using molecular approaches, all three a 2 -AR subtypes were observed in rabbit iris-ciliary body, and the a 2B -and a 2C -ARs were identified in a human ciliary body. 25 In the human ciliary epithelium, we have identified transcripts of all three a 2 -AR subtypes. 26 Collectively, these studies led to the model of the b-ARs coupling with Gs proteins to stimulate adenylyl cyclase and the a 2 -ARs coupling with Gi proteins to inhibit adenylyl cyclase in Lim homeo box transcription factor 1, beta (LMX1B) Transporters Ion channels
The glaucoma targets, their downstream signaling pathways, and possible drug metabolizing enzymes are considered. The glaucoma disease genes and disease genes with glaucoma as part of the phenotype are also candidate genes because of their potential interactions with the glaucoma drug pathways. the ciliary epithelium. However, the downstream biochemical events that mediate the complex aqueous humor secretory pathways involving ion channels and transporters are not fully elucidated. Another level of intricacy is based on heterologous cross talk between signaling pathways in the ciliary epithelium, which we demonstrated between the nitric oxide and adenylyl cyclase. 27 The SNPs within these receptors and associated pathways may impact transcription, expression, and function of these molecules.
Since the b 2 -ARs a key target regulating aqueous humor dynamics, 21 we are investigating whether SNPs in the b 2 -AR gene are genetic determinants in variation of aqueous humor dynamics. 28 Clinical significance of these SNPs is evident in pulmonary and vascular physiology. Variation in vascular response to isoproterenol indicates that the Arg16 allele correlates with enhanced agonist-mediated desensitization, and the Glu27 allele correlates with increased agonistmediated responsiveness. 29 Drysdale et al. provided evidence to suggest that b 2 -AR haplotypes, which include polymorphisms in the functionally important b 2 -AR 5 0 -cistron leader, predict the bronchodilator response in patients with asthma. 30 The Gly16 and Arg16 alleles have been examined in relation to IOP lowering and exercise. 31 To date, there are no studies reporting on the effect of the functionally important b 2 -AR SNPs in relation to response to b-AR antagonists.
In summary, both physicians and patients are well aware that the effectiveness of a particular drug in an individual may not always correlate with published efficacy and safety results from the clinical trials derived from a very homogeneous group of study subjects. Given the current availability of five different glaucoma drug classes, the ophthalmologist must consider the patient's systemic diseases and medications, comorbid ocular conditions, economic status, health insurance, impact on quality of life, and compliance issues. The anticipated promise of genetics and genomics is to determine whether predictable treatment outcomes can be assessed in the context of the complex biological and physiological interactions among expression of drug target genes, associated pathway genes, drug metabolizing enzymes, and disease genes. Since lowering IOP is an important surrogate clinical treatment outcome to protect the optic nerve that is susceptible to glaucoma, then identifying a genetic component to drug-mediated IOP lowering response has the potential for targeting subsets of patients with glaucoma to their optimal therapy with the goal of being highly effective and minimizing progressive visual field loss.
